Business Wire Industry News

Thursday, December 12, 2019

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters’ option to purchase additional common shares (the “Offering”). The

Thursday, December 12, 2019

Avivagen Secures First Order of OxC-beta™ Livestock in Malaysia

OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has secured its first order for the use of OxC-beta™ Livestock in Malaysia. The 100-kilogram order quickly follows the recent approval of OxC-beta™ Livestock for use in feed for broilers and swine in the country. “We are very pleased to announce our first order for OxC-betaTM Livestock with TLC Veterinary Services, our distribution partner in Malaysia,” says Kym Anthony, Chief Executive Office

Tuesday, December 10, 2019

BIONIK Laboratories Selects Propel to Accelerate New Product Development and Manufacturing of InMotion Robotic Systems and Services

TORONTO & BOSTON & SANTA CLARA, California--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has selected Propel, the product success platform built on Salesforce, to be its Product Lifecycle Management and Quality Management System solutions provider to accelerate new product development a

Monday, December 9, 2019

Aurinia Prices US$166.7 Million Public Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165 common shares (the “Offering”). The shares are being sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are expected to b

Monday, December 9, 2019

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding

LAVAL, Quebec--(BUSINESS WIRE)-- #Altasciences--Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder a

Monday, December 9, 2019

Aurinia Announces Public Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offering of US$150,000,000 of its common shares (the “Offering”). Jefferies LLC and SVB Leerink LLC are acting as joint book-running managers for the Offering. H.C. Wainwright & Co. LLC, Opp

Thursday, December 5, 2019

Bioasis Announces Annual General Meeting Results

GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that all resolutions we